Solid forms of an S-Nitrosoglutathione reductase inhibitor
The present invention provides solid forms and compositions thereof, which are useful as an inhibitor of S-nitrosoglutathione reductase and which exhibit desirable characteristics for the same.
1. A crystalline solid form of Compound 1,
wherein Compound 1 is a free form.
2. The crystalline solid form of claim 1 , wherein the solid form is a hemi-hydrate.
3. The crystalline solid form of claim 2 , wherein the solid form is Form A.
4. The crystalline solid form of claim 3 wherein Form A of Compound 1 is characterized by peaks in its powder X-ray diffraction pattern at about 12.9 and one or more additional peaks selected from those at about 18.0, about 18.9, about 22.6, about 23.0, about 23.7, and about 24.9 degrees 2-theta.
5. The crystalline solid form of claim 1 , wherein Compound 1 is unsolvated.
6. The crystalline solid form of claim 5 , wherein the solid form is Form B.
7. The crystalline solid form of claim 6 wherein Form B of Compound 1 is characterized by a peaks in its powder X-ray diffraction pattern at about 21.4 and one or more additional peaks selected from those at about 14.3, about 18.0, about 18.7, about 22.3, about 25.7, and about 27.6 degrees 2-theta.
8. The crystalline solid form of claim 1 , wherein Compound 1 is an IPA solvate.
9. The crystalline solid form of claim 8 , wherein the solid form is Form C.
10. The crystalline solid form of claim 9 , wherein Form C of Compound 1 is characterized by peaks in its powder X-ray diffraction pattern at about 19.4 and one or more additional peaks selected from those at about 8.1, about 11.4, about 17.7, about 18.9, about 20.5, and about 25.2 degrees 2-theta.
11. The crystalline solid form of claim 1 , wherein the solid form is form D.
12. The crystalline solid form of claim 11 , wherein Form D of Compound 1 is characterized by a peaks in its powder X-ray diffraction pattern at about 5.5 and one or more additional peaks selected from those at about 9.4, about 22.5, about 23.8, about 25.0, about 27.2, and about 27.3 degrees 2-theta.
13. A composition comprising the crystalline solid form of claim 1 and a pharmaceutically acceptable carrier or excipient.
14. A method for inhibiting S-nitrosoglutathione reductase, in a biological sample or in a patient, comprising contacting the biological sample with, or administering to the patient, a crystalline solid form according to claim 1 , or a composition thereof.
15. A method for treating a disorder or condition in a patient, comprising administering to the patient a composition according to claim 13 .
16. The method of claim 15 , wherein the disorder or condition is selected from the group consisting of cystic fibrosis, asthma, COPD, and IBD.